HC Wainwright Forecasts Fractyl Health Q1 Earnings

Key Points

• HC Wainwright forecasts Q1 2026 EPS of ($0.14), reaffirmed a Buy rating with an $8.00 price target, and models a path to profitability over the next few years (FY2026 ($0.59) → FY2028 $0.02).
• Fractyl reported a surprising Q4 2025 EPS of $0.15, beating the ($0.19) consensus by $0.34, yet the stock trades around $0.47 with a market cap of $75 million versus a consensus price target of $5.40, implying material analyst upside to the current price.
• Analyst views are mixed (three Buys, one Hold, one Sell) and institutional ownership is growing (notably General Catalyst), but investors should note TipRanks' disclosure of significant compliance risks under global anti‑corruption and sanctions laws.

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Fractyl Health in a research report issued on Wednesday, March 25th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.14) per share for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Fractyl Health's current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health's Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at $0.02 EPS.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.34.

Several other analysts also recently issued reports on GUTS. Canaccord Genuity Group restated a "buy" rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday. Morgan Stanley cut Fractyl Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Fractyl Health in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $5.40.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $0.47 on Friday. The firm has a market cap of $75.07 million, a P/E ratio of -0.26 and a beta of 1.51. The business's 50 day moving average is $0.73 and its 200-day moving average is $1.28. The company has a current ratio of 4.78, a quick ratio of 4.27 and a debt-to-equity ratio of 3.23. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Woodline Partners LP lifted its position in Fractyl Health by 47.2% during the first quarter. Woodline Partners LP now owns 516,921 shares of the company's stock worth $615,000 after purchasing an additional 165,786 shares during the period. Qube Research & Technologies Ltd bought a new position in Fractyl Health in the 2nd quarter valued at about $129,000. General Catalyst Group Management LLC bought a new position in Fractyl Health in the 2nd quarter valued at about $7,912,000. Jane Street Group LLC acquired a new position in shares of Fractyl Health in the 2nd quarter valued at approximately $31,000. Finally, Osaic Holdings Inc. raised its position in shares of Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company's stock valued at $97,000 after buying an additional 49,000 shares in the last quarter.

Key Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multiple multi‑year EPS forecasts (notably FY2026, FY2027, FY2028 and later years), reaffirmed a "Buy" rating and kept an $8.00 price target — the firm now models a path to profitability in later years, which supports upside vs. the current price. HC Wainwright research note (summary)
• Positive Sentiment: Canaccord Genuity reaffirmed its "buy" stance and a $8.00 price target, echoing bullish analyst sentiment and contributing to buying pressure. Canaccord coverage (Benzinga)
• Positive Sentiment: Media reported a notable after‑hours price surge (~21% after a recent catalyst), reflecting short‑term momentum driven by the analyst activity and investor reaction. MSN: GUTS stock jumps after hours
• Neutral Sentiment: Q4 2025 earnings call transcript is available for review (useful for details on revenue, clinical progress and management commentary). Investors should read the call for specifics behind the beats and forward commentary. Earnings call transcript
• Negative Sentiment: TipRanks flagged a new regulatory disclosure: Fractyl faces "significant compliance risks" under global anti‑corruption and sanctions laws. Such disclosures can increase legal/operational risk and weigh on sentiment if they lead to investigations or remediation costs. TipRanks: compliance risks

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.